TWD
LRMR icon

True Wealth Design’s Larimar Therapeutics LRMR Stock Holding History

True Wealth Design’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.32K Sell
726
-824
-53% -$3.19K ﹤0.01% 1625
2026
Q2 		$4.73K Buy
1,550
+1,006
+185% +$3.99K ﹤0.01% 1352
2026
Q1 		$2.45K Hold
544
– – ﹤0.01% 1459
2025
Q4 		$2.07K Buy
544
+8
+1% +$31 ﹤0.01% 1438
2025
Q3 		$1.73K Hold
536
– – ﹤0.01% 1518
2025
Q2 		$1.55K Buy
536
+226
+73% +$523 ﹤0.01% 1282
2025
Q1 		$667 Buy
+310
New +$980 ﹤0.01% 1438

Other funds holding LRMR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

True Wealth Design's LRMR Position: Q3 2026 in Review

True Wealth Design reduced its Larimar Therapeutics (LRMR) stake by 53% in Q3 2026, selling an estimated $3.19K and leaving 726 shares worth $2.32K. The position accounts for ﹤0.01% of the portfolio, ranked #1625.

True Wealth Design first reported a position in LRMR in Q1 2025 and has held it in 7 quarters since. The position peaked at $4.73K in Q2 2026. 7 funds tracked by Wall St. Rank hold LRMR as of Q3 2026.

  • True Wealth Design held 726 shares of Larimar Therapeutics worth $2.32K as of Q3 2026.
  • True Wealth Design sold 824 Larimar Therapeutics shares in Q3 2026, an estimated $3.19K.
  • Larimar Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1625 holding.
  • True Wealth Design first reported a position in Larimar Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • True Wealth Design's Larimar Therapeutics position peaked at $4.73K in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.